What is Maze Therapeutics, Inc.'s market cap?

Maze Therapeutics, Inc. (MAZE) has a market capitalization of $1.8B and trades on NASDAQ.

What is Maze Therapeutics, Inc.'s revenue and profitability?

Maze Therapeutics, Inc. generated $187.5M in trailing twelve-month revenue with a net loss of $122.5M, representing a net margin of -65.4%, with free cash flow of -$122.1M. These figures are based on the Q1 2026 filing.

Who are Maze Therapeutics, Inc.'s competitors?

Maze Therapeutics, Inc.'s key competitors include Vertex Pharmaceuticals, AstraZeneca, Compass Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Maze Therapeutics, Inc. partner with?

Maze Therapeutics, Inc.'s notable partners include Shionogi & Co., Ltd, Neurocrine Biosciences, Inc., Trace Neuroscience, Inc., and others.

What subsidiaries does Maze Therapeutics, Inc. have?

Maze Therapeutics, Inc.'s subsidiaries include Broadwing.

Where is Maze Therapeutics, Inc. headquartered?

Maze Therapeutics, Inc. is headquartered in United States of America. It has been publicly traded since 2025.

Maze Therapeutics, Inc.

MAZE

Maze Therapeutics is a clinical-stage biopharmaceutical company that utilizes its proprietary Compass platform to develop small molecule precision medicines for kidney and metabolic diseases.

Market cap

$1.79B+162%

Revenue$187.5M—

Net income-$122.5M-350%

Free cash flow-$122.1M—

EPS (diluted)-$2.48-118%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 12, 2026

Revenue$20.0MBeat by $9.4M EPS-$0.45Miss by $0.02

Read the full report

Next report

Aug 11, 2026 (in a month)

Revenue estimate$2.9M

EPS estimate-$0.76

Financials

Q1 2026

Income statement

See full

Revenue$20.0M—

Operating income-$26.6M+25.0%

Net income-$24.2M+26.2%

EPS (diluted)-$0.45+60.9%

Balance sheet

See full

Cash & equivalents$198.8M-32.5%

Total debt$61.2M+137%

Total equity$341.7M+17.0%

Total assets$419.7M+26.1%

Cash flow

See full

Operating cash flow-$39.1M-32.5%

CapEx$93.0K-68.9%

Free cash flow-$39.2M-31.5%

Valuation & ratios

Valuation

See full

Market cap$1.79B+162%

Enterprise value$1.66B+469%

P/S9.6×—

Returns & leverage

See full

Return on equity-38.7%—

Debt / equity0.2×+0.1×

Current ratio17.9×+1.8×

Segments

By geography

See full

US$20.0M—

Competitors

By market cap

Vertex Pharmaceuticals$126.01B+6.8%

Maze Therapeutics, Inc.$1.8B+238%

Septerna, Inc.$1.7B+253%

Rezolute$494.0M+14.3%

Compass Therapeutics, Inc.$416.0M+14.0%

MacroGenics$290.5M+239%

Curis$9.7M-46.9%

Alzamend Neuro, Inc.$4.4M-47.1%

By revenue growth

Septerna, Inc.+7,296%

Vertex Pharmaceuticals+10.1%

By net margin

Vertex Pharmaceuticals35.51%+42.7pp

Septerna, Inc.-49.88%+8,054pp

Maze Therapeutics, Inc.-65.36%—

Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company that utilizes its proprietary Compass platform to develop small molecule precision medicines for kidney and metabolic diseases. By integrating human genetics and variant functionalization, the company identifies genetic drivers of disease to design therapies that mimic protective variants or correct toxic ones. Their lead programs focus on genetically defined subsets of chronic kidney disease and inherited metabolic disorders.

Competitive position

Maze is a clinical-stage developer of precision medicines leveraging a proprietary functional genomics platform to target genetically validated pathways in kidney and metabolic health.

GeographiesUnited States

Customer segmentsPharmaceutical companies, Patients

Business modelR&D, Licensing, IP Monetization

SuppliersContract Manufacturing Organizations (CMOs), Genetic database providers, Laboratory equipment suppliers, Clinical trial sites

CustomersPharmaceutical licensing partners, Specialty healthcare providers, Patients with AMKD, PKU, and CKD

CountryUnited States of America

Listed2025

CEOJason Coloma

SectorHealthcare

IndustryBiotechnology

Websitemazetx.com

FilingsSEC EDGAR

Ask your AI about Maze Therapeutics, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Maze Therapeutics, Inc.'s market cap?: Maze Therapeutics, Inc. (MAZE) has a market capitalization of $1.8B and trades on NASDAQ.
What is Maze Therapeutics, Inc.'s revenue and profitability?: Maze Therapeutics, Inc. generated $187.5M in trailing twelve-month revenue with a net loss of $122.5M, representing a net margin of -65.4%, with free cash flow of -$122.1M. These figures are based on the Q1 2026 filing.
Who are Maze Therapeutics, Inc.'s competitors?: Maze Therapeutics, Inc.'s key competitors include Vertex Pharmaceuticals, AstraZeneca, Compass Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Maze Therapeutics, Inc. partner with?: Maze Therapeutics, Inc.'s notable partners include Shionogi & Co., Ltd, Neurocrine Biosciences, Inc., Trace Neuroscience, Inc., and others.
What subsidiaries does Maze Therapeutics, Inc. have?: Maze Therapeutics, Inc.'s subsidiaries include Broadwing.
Where is Maze Therapeutics, Inc. headquartered?: Maze Therapeutics, Inc. is headquartered in United States of America. It has been publicly traded since 2025.